3Grayburn PA, Erickson JM, Escobar J. Peripheral intravenous myocardial contrast echocardiography using a 2% dodecafluoropentane emulsion: identification of myocardial risk area and infarct size in the canine model of ischemia[J]. J Am Coll Cardiol, 1995, 26(5) : 1340 - 1347.
4Klibanov AL. Targeted delivery of gas-filled microspheres,contrast agents for ultrasound imaging [ J]. Adv Drug Deliv Rev, 1999, 57(1 -5):159- 157.
5Klibanov AL, Hughes MS, Villanueva FS, et al. Targeting and ultrasound imaging of microbubble-based contrast agents[J]. MAGMA, 1999, 8(3):177- 184.
6Kabalno A, Klein D, Pelura T, et al. Dissolution of multicomponent microbubbles in the bloodstream. 1.Theory[J ]. Ultrasound Med Biol, 1998, 24(5):739- 749.
7Deng CX, Lizzi FL. A review of physical phenomena associated with ultrasonic contrast agents and illustrative clinical applications[ J ]. Ultrasound Med Biol, 2002, 28( 3 ) :277-286.
8Uhlendorf V, Scholle FD, Reinhardt M. Acoustic behaviour of current ultrasound contrast agents[ J]. Ultrasonicz, 2000,38(1 -8):81 -86.
9Moran CM, Anderson T, Pye SD, at al. Quantification of microbubble destruction of three fluorocarbon-filled ultrasonic contrast agents[J]. Ultrasound Med Biol, 2,0(0, 26(4) : 629 - 639.
10hao H, Nishioka T, Fishbein MC, et al. Transcutaneous ultrasound augments lysis of arterial thrombi in vivo [ J ].Circulation, 1996, 94(4) :775 - 778.
